The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1677
ISSUE1677
May 29, 2023
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
May 29, 2023 (Issue: 1677)
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.